Research article · 2015
Research articlePublished 2017
Clinical Validation of a Serum Protein Panel (FLNA, FLNB and KRT19) for Diagnosis of Prostate Cancer
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
This study reports on the development of a novel serum protein panel of three prostate cancer biomarkers, Filamin A, Filamin B and Keratin-19 (FLNA, FLNB and KRT19) using multivariate models for disease screening and prognosis. ELISA and IPMRM (LC-MS/MS) based assays were developed and analytically validated by quantitative measurements of the biomarkers in serum. Retrospectively collected and clinically annotated serum samples with PSA values and Gleason scores were analyzed from subjects who underwent prostate biopsy, and showed no evidence of cancer with or without indication of prostatic hyperplasia, or had a definitive pathology diagnosis of prostatic adenocarcinoma. Probit linear regression models were used to combine the analytes into score functions to address the following clinical questions: does the biomarker test augment PSA for population screening? Can aggressive disease be differentiated from lower risk disease, and can the panel discriminate between prostate cancer and benign prostate hyperplasia? Modelling of the data showed that the new prostate biomarkers and PSA in combination were better than PSA alone in identifying prostate cancer, improved the prediction of high and low risk disease, and improved prediction of cancer versus benign prostate hyperplasia.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Commentary · 30 Jan 2023
At the Time of Diagnosis, Aggressive Prostate Cancer Biomarkers
Perspective · 28 Feb 2022
Role of Prostate Specific Antigen as Biomarker in Diagnosing Prostate Cancer
Conference abstract · 26 Oct 2017
Validity of prostate health index and percentage of [-2]pro-prostate-specifi c antigen as novel biomarkers in the diagnosis of prostate cancer fi rst reported Omani tertiary hospitals experience
Review article · 2016
Conventional and Promising Biomarkers for Prostate Cancer their Clinical Implication and Prospective Role
More from this journal
The newest in Journal of Molecular Biomarkers & Diagnosis.
Brief report · 29 Dec 2025
Biomarker Discovery To Clinical Translation: A Holistic Approach
Commentary · 29 Dec 2025
Molecular Diagnostics: Revolutionizing Precision Healthcare
Commentary · 29 Dec 2025
Genomic Biomarkers Revolutionizing Disease Diagnosis and Medicine
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Molecular Biomarkers & Diagnosis
- SubjectGenetics & Molecular Biology
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Shobha Ravipaty”
- BylineArticles whose byline prints “Wenfang Wu”
- BylineArticles whose byline prints “Aditee Dalvi”
- BylineArticles whose byline prints “Nikunj Tanna”
- BylineArticles whose byline prints “Joe Andreazi”
- BylineArticles whose byline prints “Tracey Friss”
- BylineArticles whose byline prints “Allison Klotz”
- BylineArticles whose byline prints “Chenchen Liao”

